Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the childcare support business, the number of children enrolled increased, benefiting from the Tokyo metropolitan government's expansion of eligibility for free childcare fees, while the number of prescriptions processed increased in the pharmaceutical business. In terms of earnings, operating profit and ordinary profit decreased due to wage increases, revisions to pharmaceutical prices and dispensing fees, soaring purchase prices, and lower profitability at hospice-care homes in the nursing care business, but interim net income increased due to the recognition of compensation for vacating premises as an extraordinary gain.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥12,458 million (YoY +3.9%) |
| Operating profit | ¥175 million (YoY -9.3%) |
| Ordinary income | ¥178 million (YoY -9.4%) |
| Profit attributable to owners of the parent | ¥145 million (YoY +4.0%) |
| Net income per share | ¥51.88 |
| Equity ratio | End of the current fiscal period 32.9 / End of previous period 25.1 |
| Total assets | ¥12,187 million |
| Net assets | ¥4,011 million |
| Cash flows from operating activities | ¥665 million |
| Cash flows from investing activities | ¥-70 million |
| Cash flows from financing activities | ¥-3,484 million |
| Cash and cash equivalents at end of period | ¥1,593 million |
| Full-year earnings forecast | Net Sales ¥25,200 million (YoY +1.4%) / Operating profit ¥600 million (YoY -27.2%) / Ordinary income ¥550 million (YoY -33.6%) / Net income ¥360 million (YoY +79.2%) |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Segment revenue | Pharmaceuticals business ¥5,004.37 thousand (YoY +3.2%), Childcare Support business ¥5,169.48 thousand (YoY +5.4%), Nursing Care business ¥1,780.05 thousand (YoY +1.2%), Other (Food business) ¥504.65 thousand (YoY +5.9%) |
| Segment profit | Pharmaceuticals business ¥167.09 thousand (YoY -17.5%), Childcare Support business ¥604.97 thousand (YoY +28.4%), Nursing Care business ¥-8.57 thousand, Other (Food business) ¥3.12 thousand (YoY -53.9%) |
| Depreciation and amortization | ¥263 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥126 thousand, Government subsidies for equipment and other assets ¥18,408 thousand, Compensation received ¥31,638 thousand / Extraordinary loss Loss on disposal of fixed assets ¥52 thousand, Bad debt loss ¥135 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 2,802,300 shares |
| Treasury Shares at Period-End | 121 shares |
| Factors Behind Changes in Business Performance | In the childcare support business, the number of children enrolled increased, benefiting from the Tokyo metropolitan government's expansion of eligibility for free childcare fees, while the number of prescriptions processed increased in the pharmaceutical business. In terms of earnings, operating profit and ordinary profit decreased due to wage increases, revisions to pharmaceutical prices and dispensing fees, soaring purchase prices, and lower profitability at hospice-care homes in the nursing care business, but interim net income increased due to the recognition of compensation for vacating premises as an extraordinary gain. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to growth in the number of children enrolled at nursery schools and an increase in the number of prescriptions processed in the pharmaceutical business. Operating profit decreased due to wage increases, higher personnel and purchase costs, revisions to pharmaceutical prices and dispensing fees, and lower profitability at hospice-care homes, but interim net income increased because compensation for vacating premises was recorded as an extraordinary gain.